Is SYK Worth Buying as Growth Improves but Execution Risks Persist?

Stryker Corporation SYK presents a growth-versus-execution decision. Second-quarter sales and earnings improved sharply as the company recovered from its first-quarter cybersecurity disruption, while margins expanded and demand remained broad.

The case is not risk-free. Cyber remediation costs, vascular supply constraints and acquisition execution still matter. For investors, the question is whether Stryker’s improving fundamentals and product pipeline justify adding exposure before those operating issues are fully resolved.

SYK’s Growth Case Is Stronger Than Its Risk Profile

Stryker delivered 9% organic sales growth in the second quarter of 2026, while adjusted earnings increased 17.9% to $3.69 per share. Adjusted operating margin rose 170 basis points year over year to 27.4%, showing that the rebound reached profitability as well as sales.

The recovery was broad. MedSurg and Neurotechnology posted 9.2% organic growth, while Orthopaedics increased 8.6%. That mix reduces dependence on a single franchise and supports management’s narrowed full-year organic sales growth outlook of 8.3% to 9.3%.

Stryker’s Valuation Is No Longer at a Historic Premium

SYK trades at 20.4X forward 12-month earnings, below its five-year median of 26.0X. That gap suggests the stock is no longer carrying the kind of premium valuation it has often commanded over the past five years.

Still, the shares are not an obvious value play. The Zacks sub-industry trades at 16.9X, leaving Stryker at a relative premium. Valuation is therefore supportive compared with SYK’s own history but less compelling against its immediate industry benchmark.

Image Source: Zacks Investment Research

SYK’s Catalysts Depend on Execution

Stryker has several product catalysts. Mako installations reached a record second-quarter level, Mako RPS moved to full commercial launch and Triathlon Gold is scaling. PROPHECY for the Incompass Total Ankle System, Pangea Trauma, LIFEPAK 35 and the planned SONOPET 3 launch broaden the growth pipeline.

Execution will determine how much of that pipeline converts into revenue. Triathlon Gold ramped more slowly after production downtime, while regulatory progress, surgeon adoption and manufacturing readiness remain important across new launches. Zimmer Biomet Holdings, Inc. ZBH is also investing in robotics, including its next-generation ROSA Shoulder System, while Intuitive Surgical, Inc. ISRG reported 16% growth in combined da Vinci and Ion procedures in its second quarter. Those developments reinforce the competitive intensity around robotic-assisted care.

Stryker’s Balance Sheet Adds Strategic Flexibility

Stryker ended the second quarter with approximately $3.5 billion of cash and marketable securities. Operating cash flow reached $1.8 billion in the first half of 2026, up from $1.4 billion a year earlier, while long-term debt declined to $14.2 billion from $14.9 billion at year-end 2025.

That liquidity supports strategic flexibility. Acquisitions remain Stryker’s primary capital-allocation priority, and management plans to resume share repurchases in the second half. The balance sheet can support growth investments while the company continues working through integration and operational recovery.

Wrapping Up

The bottom line is balanced. Stryker has stronger growth, better margins and a deep product cycle, but production ramping, peripheral vascular back orders, cyber-related costs and acquisition integration keep execution risk elevated. A disciplined stance fits that mix better than an aggressive buy-or-sell conclusion.

Currently, Stryker carries a Zacks Rank #3 (Hold). Likewise, Zimmer Biomet and Intuitive Surgical also carry a Zacks Rank of 2. Investors need to weigh Stryker’s improving earnings momentum and below-history valuation against its remaining execution demands.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research